Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients

✍ Scribed by Nemunaitis, J; Nemunaitis, M; Senzer, N; Snitz, P; Bedell, C; Kumar, P; Pappen, B; Maples, P B; Shawler, D; Fakhrai, H

• Book ID: 109842614
• Publisher: Nature Publishing Group
• Year: 2009
• Tongue: English
• Weight: 149 KB
• Volume: 16
• Category: Article
• ISSN: 0929-1903
• DOI: 10.1038/cgt.2009.15